MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme ...
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be marketed ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
Johnson & Johnson (JNJ) announced on Thursday that the U.S. FDA approved an injectable version of its cancer medicine Rybrevant, developed with Halozyme (HALO) as part of a combination regimen for ...
SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration ...
Johnson & Johnson “announced that the FDA approved RYBREVANT FASPRO, amivantamab and hyaluronidase-lpuj, the first and only subcutaneously administered therapy for patients with epidermal growth ...
Rybrevant Faspro, a subcutaneous therapy, offers a faster, less invasive treatment for EGFR-mutated NSCLC, reducing administration time and reactions compared to intravenous methods. The PALOMA-3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback